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ABSTRACT: The increase in occurrence of infections due to opportunistic gram-negative 
bacilli in patients with impaired host defences emphasizes the need for information on the 
antibiotic susceptibility of the organisms that infects such patients. Pseudomonas 
aeruginosa are becoming increasingly resistant to antimicrobial agents, and serious 
infections caused by these organisms often require immediate attention as they cause 
treatment failures. In vitro antimicrobial susceptibility data are required for successful 
therapy because acquired resistance to such antimicrobials as β-lactams, fluoroquinolones 
and aminoglycosides is so prevalent in P. aeruginosa.  The study was carried out in 
Chennai during the period May 2007 and March 2009. 69 isolates of Pseudomonas were 
isolated from HIV and 24 isolates were isolated from Non-HIV populations with lower 
respiratory tract infections. The antibiotic susceptibility pattern of all the isolates was 
studied for 12 antibiotics to find the multi drug resistant (MDR) isolates for which the 
minimum inhibitory concentration (MIC) were studied according to CLSI (2009). 
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INTRODUCTION
ᴪ 
 
A natural consequence of infectious agent is the 
antimicrobial resistance which occurs by adaptation 
of antimicrobials due to exposure in medicine used 
in farms and households
1-4.The effectiveness of the 
existing antimicrobials have declined which 
become difficult and expensive to treat the 
infection.
5-6.  Pseudomonas aeruginosa have 
emerged as an opportunistic multidrug resistant 
pathogens which is a growing problem 
worldwide
7,8. 
Lung infections caused by P. aeruginosa are 
limited to patients who are immunocompromised, 
or who have defective mucociliary clearance, 
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previous epithelial injury or foreign body 
placement. Given its ubiquitous presence in our 
environment and pathogenic potential, it is clear 
that a normally functioning host defence is very 
well adapted to prevent P. aeruginosa infection. 
Despite this, P. aeruginosa infections can be 
devastating in the hospitalized or sick. 
Understanding the failures of the host defence in 
these patients will help us understand how P. 
aeruginosa  is converted from a common 
environmental exposure to a deadly pathogen
9. 
Pseudomonas infection remains one of the 
untreatable and uncontrollable infection of the 
hospitals. Clinically it has been shown that P. 
aeruginosa has the capacity to develop resistance 
rapidly during the course of antimicrobial therapy 
by several mechanisms
10-13. Therefore, sequential 
accumulation of resistance may result in emergence 
of multidrug resistance in P. aeruginosa. Factors 
influencing the emergence and spread of acquired Chandrahausan et al / Resistance patterns of Pseudomonas aeruginosa 
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resistance in P. aeruginosa include inadequate and 
overuse of antimicrobials
14. 
The steady rise in adaptive and mutational 
resistance is increasingly impacting on therapeutic 
success and new antimicrobial therapeutic options 
are needed for resistant strains, some of which have 
developed resistance to virtually every type of 
antibiotic and have thus become hospital 
‘superbugs’
15. So this study was undertaken in 
order to assess the current level of susceptibility of 
widely used antipseudomonal antibiotics against P. 
aeruginosa. 
 
METHODOLOGY 
 
Bacterial strains 
 
Sixty-nine consecutive, Pseudomonas spp. isolates 
were collected between May 2007 and March 2009 
from sputum samples from HIV patients was 
collected from Government hospital of thoracic 
medicine, Tambaram  sanatorium, Chennai. 
Sputum samples from Non-HIV patients were 
collected from Government Stanley hospital, 
Chennai and Dr.Kamashi Memorial hospital, 
Chennai. All isolates were identified according to 
standard protocol of CLSI 2009. All cultures were 
incubated at 37
0C for 24 - 48 h for isolation of 
Pseudomonas spp. Of these isolates, 45 were from 
HIV and 24 from non-HIV patients. The study was 
approved by the institutional ethical committee and 
informed consent was obtained from patients. 
 
Antibiotic susceptibility testing-disc diffusion 
method 
 
Antibiotic susceptibility testing was done by Kirby 
Bauer disc diffusion method as per Clinical 
Laboratory Standard Institute (CLSI) guidelines 
2009. The following antipseudomonal antibiotics 
were used to screen for multidrug resistance among 
the isolates. The antibiotics included were 
piperacillin (100µg), cefotaxime (30µg), 
ceftazidime (30µg), cefoperazone (75µg), 
tobramycin (30µg), ceftriaxone (30µg), amikacin 
(30µg), netilmicin (30µg), ofloxacin (5µg), 
ciprofloxacin (5µg), imipenem (10µg), mezlocillin 
(75µg), azlocillin (75µg), ticarcillin (75µg). 
 
MIC (Micro-Broth Dilution Method) 
 
The MIC was done for the following antibiotics: 
ceftazidime, cefoperazone, cefotaxime (Orchid 
Pharmaceuticals Ltd), amikacin and ciprofloxacin 
(Hi Media laboratories ltd.). MICs were determined 
by micro broth dilution method as per CLSI 
guidelines using cation adjusted Mueller Hinton 
broth (CMHB, Difco) at pH 7.0. The antibiotics 
with various dilutions were prepared from the stock 
solutions and the inocula were prepared according 
to CLSI standards. Minimal inhibitory 
concentration (MIC) was visually read after 24 hrs 
of incubation at 37
0C. MIC was defined as the 
lowest drug concentration resulting in 90% 
reduction in turbidity when compared to the drug 
free control. Minimum bactericidal concentration 
(MBC) was also done for further confirmation. 
The final concentrations of the antibiotics ranged 
from 0.25µg/ml to 256µg/ml. P. aeruginosa ATCC 
27853 was included as the quality control strain. 
Interpretive criteria for resistance to various 
antibiotics according to CLSI guidelines were as 
follows: ceftazidime (≥ 32µg/ml), cefotaxime 
(64µg/ml) cepoferazone (≥ 64µg/ml), amikacin (≥ 
64µg/ml), and ciprofloxacin (≥ 4µg/ml). 
 
RESULTS 
 
A total of 71 respiratory isolates of pseudomonas 
spp. were isolated both from HIV and Non-HIV 
patients with lower respiratory tract infection over 
the period of May 2007-March 2009. Among the 
71 isolates 44 were Pseudomonas aeruginosa 19 
were Pseudomonas stutzeri, 8 were Pseudomonas 
putida 1 were Alcaligenes faecalis Out of 71/45 
were from HIV population, 24 were from Non-HIV 
and 2 were environmental isolates. A standard 
strain of ATCC was used as control. All the 71 
(22.76%) isolates were examined for the antibiotic 
sensitivity against 15 antipseudomonal antibiotics. 
Table 1 shows that among the 45 HIV isolate 
tested, 37 (82.2%) showed resistance to 
ceftazidime, 30/45 (66.7%) showed resistance for 
mezlocillin. Ceftriaxone and cefotaxime resistance 
was shown by 29/45(64.4%), resistance to 
cefoperazone was shown by 27/45 (60%), whereas 
21/45 (46.7%) showed resistance to ticarcillin. 
10/45 (22.2%) showed resistance to, ciprofloxacin 
and piperacillin. 9/46 (20%) showed resistance to 
amikacin and azlocillin. 7/45 (15.6%) isolates 
showed resistance towards tobramycin and 
ofloxacin, 5/45 (11.1%) showed resistance to 
netilmicin. All the 45 isolates showed 100% 
sensitivity to imipenem. 
Table 2 shows that non HIV isolates showed 
highest resistance to cefotaxime and mezlocillin 
21/24(87.5%), they showed intermediate resistance 
to ceftazidime and ticarcillin 18/24 (75%) followed 
by resistance to cefoperazone16/24 (66.7%). 
Azlocillin and ceftriaxone showed 11/24 (45.8%) 
resistance. 8/24 (33.3%) isolates showed resistance 
to piperacillin, while 3/24 (12.5%) showed 
resistance to amikacin followed by 2/24 (8.3%) 
resistance towards ciprofloxacin and imipenem. 
The least resistance was observed for ofloxacin 
1/24 (4.17%). 
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Table 1: Resistance pattern exhibited by Pseudomonas spp. among HIV patients to various antibiotics 
 
Antibiotics group  Antibiotics in µg  Number of strains resistant to 
antibiotics (%) 
Carbapenems Imipenem  (10µg)  0  (0) 
Cephalosporin 
Ceftazidime (30µg)  37 (82.2) 
Cefotaxime (30µg)  29 (64.4) 
Cefoperazone (75µg)  27 (60.0) 
Ceftriaxone (30µg)  29 (64.4) 
Aminoglycosides 
Amikacin (30µg)  9 (20.0) 
Tobramycin (30µg)  7 (15.6) 
Netilmicin (30µg)  5 (11.1) 
Fluoroquinolones 
Ofloxacin (5µg )  7 (15.6) 
Ciprofloxacin (5µg)  10 (22.2) 
Penicillin group 
Piperacillin (100µg)  10 (22.2) 
Mezlocillin (75µg)  30 (66.7) 
Azlocillin (75µg)  9 (20.0) 
Ticarcillin (75µg)  21 (46.7) 
 
Table 2: Resistance pattern exhibited by Pseudomonas spp. among Non-HIV patients to various 
antibiotics 
 
Antibiotics group  Antibiotics in µg  Number of strains resistant to 
antibiotics (%) 
Carbapenems Imipenem  (10µg)  2  (8.3) 
Cephalosporin 
Ceftazidime (30µg)  18 (75.0) 
Cefotaxime (30µg)  21 (87.5) 
Cefoperazone (75µg)  16 (66.7) 
Ceftriaxone (30µg)  11 (45.83) 
Aminoglycosides 
Amikacin (30µg)  3 (12.5) 
Tobramycin (30µg)  4 (16.7) 
Netilmicin (30µg)  4 (16.7) 
Fluoroquinolones 
 
Ofloxacin (5µg )  1 (4.2) 
Ciprofloxacin (5µg)  2 (8.3) 
Penicillin group 
Piperacillin (100µg)  8 (33.3) 
Mezlocillin (75µg)  21 (87.5) 
Azlocillin (75µg)  11 (45.8) 
Ticarcillin (75µg)  18 (75) 
 
 
Minimum inhibitory concentration by micro broth 
dilution method (MIC):  The MIC for the 
antibiotics was tested by micro broth dilution 
method according to CLSI guidelines 2008. Among 
HIV isolates tested, 37 isolates which showed 
resistance for ceftazidime were taken for MIC 
studies of third generation cephalosporin. 13 
(35.13%) showed resistance in our MIC studies. Chandrahausan et al / Resistance patterns of Pseudomonas aeruginosa 
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Thirteen out of 30 isolates (35.13%) showed 
resistance for cefotaxime and 17 out of 27 isolates 
(62.96%) were resistant to cefoperazone. 4 
(40%)isolates showing ciprofloxacin resistance and 
1(11.11%) out of 9 strains showed resistance to 
amikacin. (Table 3) 
 
Table 3: MIC for HIV isolates 
 
Antibiotics S I  R 
MIC Break 
points 
S I R 
Ceftazidime 
(N=37)  21 3 13 ≤8 16  >32 
Cefotaxime 
(N=29)  4 12  13  8  16-
32  64 
Cefoperazone 
(N=27)  9 1  17 16 32  ≥64 
Ciprofloxacin 
(N=10)  - 7 4 ≤1 2 ≥4 
Amikacin 
(N=9)  9 - -  ≤16 32 ≥64 
 
In non HIV isolates, 2 out of 16 isolates (12.5%) 
tested showed resistance by MIC for cefoperazone, 
100% sensitivity was seen for ciprofloxacin, 4 
(19.04%) out of 21 isolates showed resistance by 
MIC in our study for  cefotaxime.16 out of 18 
isolates (88.89%) showed resistance by  MIC for 
ceftazidime. (Table 4) 
 
Table 4: MIC for Non-HIV isolates 
 
Antibiotics S I  R 
MIC Break 
points 
S I R 
Ceftazidime 
(N=18)  2 -  16  ≤8 16  >32 
Cefotaxime 
(N=21)  10 17 4  8  16-
32  64 
Cefoperazone 
(N=16)  13 1 2  16  32 ≥64 
Ciprofloxacin 
(N=2)  1 1 - ≤1 2 ≥4 
Amikacin 
(N=3)  3 - -  ≤16 32 ≥64 
 
 
DISCUSSION 
 
As resistance among P. aeruginosa continues to 
increase globally, novel dosage strategies will be 
needed to retain the effectiveness of currently 
available antibiotics. Pseudomonas is inherently 
resistant to many antimicrobial Agents. The rate of 
strains with acquired resistance to ceftazidime has 
been estimated to range from 10% to 40%
16. Our 
rate of ceftazidime resistance was 35.13%.the 
development of antibiotic resistance is very 
common during the course of treatment. Our results 
demonstrate that half of our isolates are multiple 
resistant both in HIV and in non-HIV population. 
These data indicate that a high number of isolates 
probably have resistance due to impermeability or 
multi-drug efflux or a combination of multiple 
unrelated resistance mechanisms. Ciprofloxacin 
showed the highest in vitro antibacterial activity 
followed by amikacin among the non HIV 
population whereas in HIV population only 
amikacin showed the highest antibacterial activity 
than ciprofloxacin in our centre
11,17,18. These data 
indicate that a high number of isolates probably 
have resistance due to impermeability or multi-drug 
efflux or a combination of multiple unrelated 
resistance mechanisms. 
Although comparison between studies is difficult 
since patient populations of centres and methods of 
studying differ, interestingly, we found a higher 
level of resistance to cephalosporin group by disc 
diffusion method followed by penicillin group. 
Aminoglycosides and fluoroquinolones showed the 
least resistance. Whereas in MIC we noticed that in 
HIV isolates ciprofloxacin resistance was high 
compared to non-HIV isolates, in HIV 
cefoperazone showed the highest resistance by 
MIC followed by cefotaxime and ceftazidime 
compared to non-HIV where it was seen for 
ceftazidime followed by cefotaxime and 
cefoperazone
19-22. The incidence of resistance is 
dependent on the patterns of antibiotic usage. 
Our findings suggest that imipenem, amikacin and 
ciprofloxacin may be of significant value for the 
treatment of severe infections caused by P. 
aeruginosa. Though resistance to imipenem has 
developed in our study we did not find any 
imipenem resistance both in HIV and Non-HIV 
isolates tested. So imipenem remains the drug of 
choice for treatment in most of the severe cases and 
may be more useful than β-lactams for combined 
treatment. 
 
CONCLUSION 
 
The prevalence of ceftazidime resistance in our 
study was 35.13% compared to other studies. There 
is a higher level of resistance among the HIV 
population than non-HIV population which may be 
due to the varying usage of antibiotics to treat 
infections in immunocompromised hosts. Hence 
there is a need for periodic surveillance of 
antibiotic resistance patterns and efforts to decrease 
empirical antibiotic therapy. 
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